The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.
 
Adam Jacob Schoenfeld
No Relationships to Disclose
 
Joseph Minhow Chan
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Natasha Rekhtman
No Relationships to Disclose
 
Yahya Daneshbod
No Relationships to Disclose
 
Daisuke Kubota
No Relationships to Disclose
 
Jason C. Chang
No Relationships to Disclose
 
Maria E. Arcila
Honoraria - Invivoscribe
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Invivoscribe; Raindance Technologies
 
Marc Ladanyi
Honoraria - Merck (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck (I); NCCN/AstraZeneca; Takeda
Research Funding - Helsinn Therapeutics; Loxo (Inst)
 
Romel Somwar
Research Funding - Helsinn Healthcare
Travel, Accommodations, Expenses - Helsinn Healthcare
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Memorial Sloan-Kettering Cancer Center
 
Dana Pe'er
No Relationships to Disclose
 
Gregory J. Riely
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Lilly
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly